和黄医药:完成赛沃替尼(savolitinib)用于治疗胃癌的中国II期注册研究的患者入组

格隆汇
Yesterday

格隆汇4月22日丨和黄医药(00013.HK)发布公告,赛沃替尼用于治疗MET扩增胃癌患者的II期研究的注册阶段已完成患者入组。该临床试验是一项单臂、多中心、开放标签的II期注册研究,旨在评估赛沃替尼用于治疗伴有MET扩增的胃癌和胃食管结合部(GEJ)腺癌的疗效、安全性和耐受性。研究的主要终点为独立审查委员会(IRC)评估的客观缓解率(“ORR”)(依据RECIST 1.1进行评估) 。次要终点...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10